Middle East & Africa Preclinical Cro Market Size & Outlook
Middle East & Africa preclinical cro market, 2018-2030 (US$M)
Related Markets
MEA preclinical cro market highlights
- The MEA preclinical cro market generated a revenue of USD 55.1 million in 2023.
- The market is expected to grow at a CAGR of 4.4% from 2024 to 2030.
- In terms of segment, toxicology testing was the largest revenue generating service in 2023.
- Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 55.1 million |
| Market revenue in 2030 | USD 74.6 million |
| Growth rate | 4.4% (CAGR from 2023 to 2030) |
| Largest segment | Toxicology testing |
| Fastest growing segment | Bioanalysis and DMPK studies |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.0% of the global preclinical cro market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,865.2 million by 2030.
Toxicology testing was the largest segment with a revenue share of 22.5% in 2023. Horizon Databook has segmented the Middle East & Africa preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
A growing population and favorable government initiatives to increase access to healthcare are expected to attract global biopharmaceutical and medical companies to enter this market. As an increasing number of biopharmaceutical and medical device companies are outsourcing their R&D services in the region, the number of clinical trials is expected to grow.
An increasing number of R&D projects & CROs and the growing number of pharmaceutical & biotechnology companies in the region are expected to boost market growth during the forecast period. The country is adopting global standards and collaborating with other global CROs to mark its market presence.
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
MEA preclinical cro market size, by country, 2018-2030 (US$M)
Middle East & Africa Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
